本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Lyell Immunopharma, Inc.

15.49
+0.75005.09%
盤後15.490.00000.00%19:30 EDT
成交量:10.30萬
成交額:158.54萬
市值:3.80億
市盈率:-1.31
高:15.68
開:15.02
低:14.92
收:14.74
52周最高:45.00
52周最低:10.56
股本:2,450.44萬
流通股本:1,079.14萬
量比:0.59
換手率:0.95%
股息:- -
股息率:- -
每股收益(TTM):-11.8281
每股收益(LYR):-16.0562
淨資產收益率:-93.28%
總資產收益率:-34.18%
市淨率:1.62
市盈率(LYR):-0.96

資料載入中...

2026/08/14

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/07

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/06

重要事件披露

Form 8-K - Current report
2026/07/18

SEC問詢函

Form CORRESP - Correspondence
2026/06/18

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/06/15

重要事件披露

Form 8-K - Current report
2026/05/15

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/11

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/08

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/07

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/05/07

重要事件披露

Form 8-K - Current report
2026/04/21

超過5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/04/13

SEC問詢函

Form CORRESP - Correspondence
2026/03/13

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/03/13

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/03/13

重要事件披露

Form 8-K - Current report
2026/03/09

重要事件披露

Form 8-K - Current report
2025/12/12

SEC問詢函

Form CORRESP - Correspondence
2025/12/08

重要事件披露

Form 8-K - Current report
2025/12/05

重要事件披露

Form 8-K - Current report